Kezar Life Sciences Inc
KZR4.070USD
+0.020+0.49%
交易中 （美东）报价延迟15分钟
29.73M总市值
亏损市盈率 TTM
关于 Kezar Life Sciences Inc 公司
Kezar Life Sciences, Inc. 是一家临床阶段的生物制药公司，专注于发现和开发小分子疗法，以治疗免疫介导疾病和癌症中未满足的需求。该公司的主要候选产品 zetomipzomib 是一种同类首创的选择性免疫蛋白酶体抑制剂，已完成健康志愿者的 Ia 期测试和系统性红斑狼疮 (SLE) 患者（伴或不伴狼疮性肾炎 (LN)）的 Ib/IIa 期临床试验。其肿瘤候选产品 KZR-261 是一种小分子药物，靶向 Sec61 转运蛋白和蛋白质分泌途径，正在进行一项开放标签 I 期临床试验，旨在评估安全性和耐受性、药代动力学和药效学，以及探索初步的抗肿瘤活性。这项研究分为两部分进行：对局部晚期或转移性实体恶性肿瘤患者的剂量递增，以及对选定肿瘤类型患者的剂量扩大。
公司简介
公司代码KZR
公司名称Kezar Life Sciences Inc
上市日期Jun 21, 2018
CEODr. Christopher Kirk, Ph.D.
员工数量55
证券类型Ordinary Share
年结日Jun 21
公司地址4000 Shoreline Ct Ste 300
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编94080-2005
电话16508225600
网址https://kezarlifesciences.com/
公司代码KZR
上市日期Jun 21, 2018
CEODr. Christopher Kirk, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. John Franklin Fowler
Mr. John Franklin Fowler
Director
Director
43.61K
--
Dr. Michael G. Kauffman, M.D., Ph.D.
Dr. Michael G. Kauffman, M.D., Ph.D.
Independent Director
Independent Director
6.37K
--
Mr. Marc L. Belsky
Mr. Marc L. Belsky
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
1.87K
-0.05%
Dr. Christopher Kirk, Ph.D.
Dr. Christopher Kirk, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Micki Klearman, M.D.
Dr. Micki Klearman, M.D.
Independent Director
Independent Director
--
--
Mr. Franklin M. Berger
Mr. Franklin M. Berger
Independent Director
Independent Director
--
--
Mr. Graham K. Cooper
Mr. Graham K. Cooper
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Courtney Wallace
Ms. Courtney Wallace
Independent Director
Independent Director
--
--
Mr. Mark Schiller
Mr. Mark Schiller
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Elizabeth Garner, M.D.
Dr. Elizabeth Garner, M.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. John Franklin Fowler
Mr. John Franklin Fowler
Director
Director
43.61K
--
Dr. Michael G. Kauffman, M.D., Ph.D.
Dr. Michael G. Kauffman, M.D., Ph.D.
Independent Director
Independent Director
6.37K
--
Mr. Marc L. Belsky
Mr. Marc L. Belsky
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
1.87K
-0.05%
Dr. Christopher Kirk, Ph.D.
Dr. Christopher Kirk, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Micki Klearman, M.D.
Dr. Micki Klearman, M.D.
Independent Director
Independent Director
--
--
Mr. Franklin M. Berger
Mr. Franklin M. Berger
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月2日 周三
更新时间: 7月2日 周三
持股股东
股东类型
持股股东
持股股东
占比
Tang Capital Management, LLC
9.86%
Suvretta Capital Management, LLC
9.81%
Equal Talent Investments, Ltd.
8.44%
Avidity Partners Management LP
6.88%
BML Capital Management LLC
5.59%
Other
59.43%
持股股东
持股股东
占比
Tang Capital Management, LLC
9.86%
Suvretta Capital Management, LLC
9.81%
Equal Talent Investments, Ltd.
8.44%
Avidity Partners Management LP
6.88%
BML Capital Management LLC
5.59%
Other
59.43%
股东类型
持股股东
占比
Hedge Fund
36.09%
Investment Advisor
14.23%
Corporation
8.44%
Investment Advisor/Hedge Fund
5.63%
Private Equity
2.64%
Individual Investor
2.16%
Research Firm
0.47%
Other
30.35%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
206
5.15M
70.50%
-1.72M
2025Q1
258
5.21M
71.33%
-2.10M
2024Q4
278
5.09M
69.66%
-2.04M
2024Q3
292
4.99M
68.49%
-2.51M
2024Q2
303
5.03M
68.99%
-2.99M
2024Q1
309
5.63M
77.32%
-2.93M
2023Q4
309
6.08M
83.70%
-2.64M
2023Q3
309
6.63M
91.19%
-2.23M
2023Q2
309
7.09M
97.92%
-2.02M
2023Q1
307
7.44M
107.15%
-1.11M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Tang Capital Management, LLC
720.00K
9.86%
--
--
Mar 31, 2025
Suvretta Capital Management, LLC
716.76K
9.81%
--
--
Mar 31, 2025
Equal Talent Investments, Ltd.
616.50K
8.44%
--
--
Feb 28, 2025
Avidity Partners Management LP
502.60K
6.88%
--
--
Mar 31, 2025
BML Capital Management LLC
408.14K
5.59%
+39.54K
+10.73%
Mar 31, 2025
The Vanguard Group, Inc.
276.23K
3.78%
+2.12K
+0.77%
Mar 31, 2025
OrbiMed Advisors, LLC
192.70K
2.64%
--
--
Mar 31, 2025
Adar1 Capital Management LLC
147.40K
2.02%
--
--
Mar 31, 2025
Acadian Asset Management LLC
133.53K
1.83%
-12.14K
-8.33%
Mar 31, 2025
Peapod Lane Capital LLC
124.43K
1.7%
+433.00
+0.35%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Value ETF
0%
iShares Biotechnology ETF
0%
ProShares UltraPro Russell2000
0%
ALPS Medical Breakthroughs ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 3000 ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
查看更多
iShares Micro-Cap ETF
占比0.01%
iShares Russell 2000 Value ETF
占比0%
iShares Biotechnology ETF
占比0%
ProShares UltraPro Russell2000
占比0%
ALPS Medical Breakthroughs ETF
占比0%
ProShares Hedge Replication ETF
占比0%
Proshares Ultra Russell 2000
占比0%
iShares Russell 3000 ETF
占比0%
Invesco Nasdaq Biotechnology ETF
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Oct 28, 2024
Merger
10<1
Oct 28, 2024
Merger
10<1
Oct 28, 2024
Merger
10<1
Oct 28, 2024
Merger
10<1
公告日期
类型
比率
Oct 28, 2024
Merger
10<1
Oct 28, 2024
Merger
10<1
Oct 28, 2024
Merger
10<1
Oct 28, 2024
Merger
10<1
